Faron Pharmaceuticals: Encouraging Study Update From BEXMAB - Redeye

Redeye leaves a note following an announced trial update from the phase I/II BEXMAB study with lead candidate Bexmarilimab. Redeye is encouraged by continued positive development and findings from the study.

Länk till analysen i sin helhet: https://www.redeye.se/research/867527/faron-pharmaceuticals-encouraging-study-update-from-bexmab?utm_source=finwire&utm_medium=RSS